The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01358357




Registration number
NCT01358357
Ethics application status
Date submitted
19/05/2011
Date registered
23/05/2011
Date last updated
7/09/2016

Titles & IDs
Public title
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
Scientific title
A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder
Secondary ID [1] 0 0
2011-000986-10
Secondary ID [2] 0 0
D1050296
Universal Trial Number (UTN)
Trial acronym
PERSIST
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bipolar I Disorder 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lurasidone
Treatment: Drugs - Placebo

Experimental: Lurasidone 20-80 mg flexible dose -

Placebo Comparator: Placebo -


Treatment: Drugs: Lurasidone
Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter

Treatment: Drugs: Placebo
20-80 mg flexible dose

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Recurrence of Mood Event During the Double Blind Treatment Phase - A mood event is defined as one of the following during the double-blind phase:
(1) Fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision (DSM-IV-TR) criteria for manic, mixed manic, hypomanic, or depressive episode. (2) Required treatment intervention for manic, mixed manic, hypomanic, or depressive symptoms with any antipsychotic (other than study drug), antidepressant, mood stabilizer (other than lithium or divalproex), anxiolytic agents, benzodiazepine (beyond dosage allowed for anxiety, agitation, or insomnia). (3) Psychiatric hospitalization for any bipolar mood episode. (4) Young Mania Rating Scale (YMRS) or Montgomery-Asberg Depression Rating Scale (MADRS) total score = 18 or Clinical Global Impression Bipolar Version, Severity of Illness (CGI BP S) score = 4 at 2 consecutive assessments no more than 10 days apart. (5) Discontinuation from the study because of a mood event (as determined by the Investigator).
Timepoint [1] 0 0
28 weeks (up to 33 weeks)
Secondary outcome [1] 0 0
Time to All-cause Discontinuation
Timepoint [1] 0 0
28 weeks (up to 33 weeks)
Secondary outcome [2] 0 0
Time to Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
Timepoint [2] 0 0
28 weeks (up to 33 weeks)
Secondary outcome [3] 0 0
Percentage of Subjects Who Experience a Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
Timepoint [3] 0 0
28 weeks
Secondary outcome [4] 0 0
Change From Double-blind Baseline to Week 28 (LOCF) in CGI-BP-S Overall Score - The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1=Normal, not at all ill, to 7=Among the most extremely ill patients. a higher score is associated with greater illness severity.
Timepoint [4] 0 0
Double-blind Baseline to week 28
Secondary outcome [5] 0 0
Change From Double -Blind Baseline to Week 28 (LOCF) in CGI-BP-S Mania Score - The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A high score is associated with greater illness severity
Timepoint [5] 0 0
Double-blind Baseline to week 28
Secondary outcome [6] 0 0
Change From Double-blind Baseline to Week 28 (LOCF) in CGI+-BP-S Depression Score - The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with a greater illness severity.
Timepoint [6] 0 0
Double-blind Baseline to week 28
Secondary outcome [7] 0 0
Change From Double-blind Baseline to Week 28 (LOCF) in YMRS Total Score - the YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of maia.
Timepoint [7] 0 0
Double-blind Baseline to week 28
Secondary outcome [8] 0 0
Change From Double-blind Baseline to Week 28 (LOCF) in MADRS Total Score - The MADRS consists of 10 items, each rated on a Likert scale, from 0=Normal to 6=Most Severe. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depressive symptoms.
Timepoint [8] 0 0
Double-blind Baseline to week 28
Secondary outcome [9] 0 0
Change Fro Double-blind Baseline to Week 28 (LOCF) in QIDS-SR(16) Total Score - The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms.
Timepoint [9] 0 0
Double-blind Baseline to week 28
Secondary outcome [10] 0 0
Change From Double-blind Baseline to Week 28 (LOF) in PANSS Positive Symptom (PANNS-P) Subscale Score - The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Timepoint [10] 0 0
Double-blind Baseline to week 28
Secondary outcome [11] 0 0
Change From Double-blind Baseline to Week 28 (LOCF) in SDS Total Score - The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing.
Timepoint [11] 0 0
Double-blind Baseline to week 28
Secondary outcome [12] 0 0
Change From Double-blind Baseline to Week 28 (LOCF) in PIRS-2 Total Score - The PIRS-2 is a 2-item self-report of insomnia assessed via a computer interface. Each item is scored from 0-3. The PIRS-2 total score is calculated as the sum of the 2 items. The PIRS total score ranges from 0 to 6. Higher scores are associated with greater severity of insomnia.
Timepoint [12] 0 0
Double-blind Baseline to week 28
Secondary outcome [13] 0 0
Change From Double-blind Baseline to Week 28 (LOCF) in Q-LES-Q-SF Percent Maximum Possible Score - The Q-LES-Q-SF is a 16-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living. The questionnaire was developed and validated for use in depressed outpatient subjects and has eight summary scales that reflect major areas of functioning: physical health, mood, leisure time activities, social relationships, general activities, work, household duties and school/coursework. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The Q-LES-Q-SF percentage maximum possible score is calculated as 100 × (Raw Score - 14 [Minimum Score]) / (70 [Maximum Score] - 14 [Minimum Score]). Higher percent maximum scores indicate better quality of life.
Timepoint [13] 0 0
Double-blind Baseline to week 28

Eligibility
Key inclusion criteria
Open-label Phase

- 18 years of age or older

- Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision
(DSM-IV-TR) diagnosis of bipolar I disorder

•= 1 manic, mixed manic, or depressed episode in past 2 years

- YMRS or MADRS total score = 14 if on lithium or divalproex; = 18 if not on lithium or
divalproex

Double-blind Phase



- Subjects must achieve consistent clinical stability, defined as total scores = 12 on
the YMRS and MADRS over at least 12 weeks, with the allowance of two excursions (YMRS
and/or MADRS total scores up to 13 or 14, respectively) except during the last 4 weeks
before randomization
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Open Label Phase

- Diagnosis of an Axis I or Axis II disorder, other than bipolar I disorder, that is the
primary focus of treatment within 3 months of screening

- Subjects for whom diagnostic agreement between the Investigator and United BioSource
Corporation (Boston) (UBC) cannot be reached

- Ultra-fast rapid cycling (defined as = 8 mood episodes over the previous 12-month
period)

- Subjects who test positive for drugs of abuse at screening. In the event a subject
tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate
the subject's ability to abstain from cannabis during the study

- Unstable/inadequately treated medical illness

- The subjects answers "yes" to "Suicidal Ideation" items 4 or 5 on the C-SSRS (at time
of evaluation)

Double Blind Phase

- Subjects who in the Investigator's judgment have not been compliant with study
medication during the stabilization phase

- Subjects who have not stabilized during the open-label phase (within 20 weeks)

- Subjects who test positive for drugs of abuse at double-blind phase baseline. In the
event a subject tests positive for cannabinoids (tetrahydrocannabinol), the
Investigator will evaluate the subject's ability to abstain from cannabis during the
study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Recruitment hospital [1] 0 0
The Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [2] 0 0
RWF Medic Pty Ltd as Trustee for Farnbach Family Trust at Neurotherapy Victoria - Malvern
Recruitment hospital [3] 0 0
The Melbourne Clinic - Richmond
Recruitment hospital [4] 0 0
Hollywood Medical Centre - Fremantle
Recruitment postcode(s) [1] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [2] 0 0
3144 - Malvern
Recruitment postcode(s) [3] 0 0
3121 - Richmond
Recruitment postcode(s) [4] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Oklahoma
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Rhode Island
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Argentina
State/province [16] 0 0
Provincia de Cordoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa Fe
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Cordoba
Country [20] 0 0
Argentina
State/province [20] 0 0
La Plata
Country [21] 0 0
Argentina
State/province [21] 0 0
Mendoza
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Bourgas
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Plovdiv
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Rousse
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Sofia
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Varna
Country [27] 0 0
Chile
State/province [27] 0 0
Santiago
Country [28] 0 0
Croatia
State/province [28] 0 0
Rijeka
Country [29] 0 0
Croatia
State/province [29] 0 0
Zagreb
Country [30] 0 0
Croatia
State/province [30] 0 0
Zagreg
Country [31] 0 0
Czech Republic
State/province [31] 0 0
Brno-Bohunice
Country [32] 0 0
Czech Republic
State/province [32] 0 0
Brno
Country [33] 0 0
Czech Republic
State/province [33] 0 0
Havirov
Country [34] 0 0
Czech Republic
State/province [34] 0 0
Pisek
Country [35] 0 0
Czech Republic
State/province [35] 0 0
Prague 8-Bohunice
Country [36] 0 0
Czech Republic
State/province [36] 0 0
Prague
Country [37] 0 0
Czech Republic
State/province [37] 0 0
Praha 10
Country [38] 0 0
Czech Republic
State/province [38] 0 0
Praha 3
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Praha 4
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Prerov
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Usti nad labem
Country [42] 0 0
France
State/province [42] 0 0
Dijon cedex
Country [43] 0 0
France
State/province [43] 0 0
Dole
Country [44] 0 0
France
State/province [44] 0 0
Montpellier Cedex 5
Country [45] 0 0
France
State/province [45] 0 0
Nimes Cedex 09
Country [46] 0 0
Hungary
State/province [46] 0 0
Budapest
Country [47] 0 0
Hungary
State/province [47] 0 0
Gyor
Country [48] 0 0
Hungary
State/province [48] 0 0
Gyula
Country [49] 0 0
Japan
State/province [49] 0 0
Gunma
Country [50] 0 0
Japan
State/province [50] 0 0
Hokkaido
Country [51] 0 0
Japan
State/province [51] 0 0
Nagano
Country [52] 0 0
Japan
State/province [52] 0 0
Osaka
Country [53] 0 0
Japan
State/province [53] 0 0
Saga
Country [54] 0 0
Japan
State/province [54] 0 0
Tokyo
Country [55] 0 0
Japan
State/province [55] 0 0
Aichi
Country [56] 0 0
Japan
State/province [56] 0 0
Hachioji, Tokyo
Country [57] 0 0
Japan
State/province [57] 0 0
Kumamoto
Country [58] 0 0
Japan
State/province [58] 0 0
Okinawa
Country [59] 0 0
Japan
State/province [59] 0 0
Toyama
Country [60] 0 0
Poland
State/province [60] 0 0
Gdynia
Country [61] 0 0
Poland
State/province [61] 0 0
Kielce
Country [62] 0 0
Poland
State/province [62] 0 0
Torun
Country [63] 0 0
Poland
State/province [63] 0 0
Tuszyn
Country [64] 0 0
Poland
State/province [64] 0 0
Wroclaw
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Izhevsk
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Nizhniy Novgorod
Country [67] 0 0
Russian Federation
State/province [67] 0 0
St. Petersburg
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Tomsk
Country [69] 0 0
Serbia
State/province [69] 0 0
Belgrade
Country [70] 0 0
Serbia
State/province [70] 0 0
Kragujevac
Country [71] 0 0
Serbia
State/province [71] 0 0
Nis
Country [72] 0 0
Serbia
State/province [72] 0 0
Novi Knezevac
Country [73] 0 0
Slovakia
State/province [73] 0 0
Rimavska Sobota
Country [74] 0 0
Slovakia
State/province [74] 0 0
Zlate Moravce

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sunovion
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multi-center, randomized, placebo-controlled, flexible-dose, parallel-group study
designed to evaluate the efficacy and safety of lurasidone (in combination with lithium or
divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without
rapid cycling and /or psychotic features.
Trial website
https://clinicaltrials.gov/show/NCT01358357
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director, MD
Address 0 0
Sunovion
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications